Nutritional styles as Mediterranean and DASH diets are associated with lower incidences of certain chronic diseases and long life expectancy. The reason lays on their di erent contribution in bers, polyphenols (from ff fi vegetables and fruit) and proteins. Barley is high ber cereal that contains high amount of -glucans and infi β soluble bers that it was recognized having healthy bene ts.
1. Introduction
Functional food and diet
The functional food science has recently gained great relevance in response to the changing health status of developed countries. This new field of nutrition combines food knowledge with health and human physiology to contrast or delay ageing and age-related diseases (Aiello et al., 2016) .
Many functional foods are part of well studied dietary patterns, such as Mediterranean Diet and Dietary Approaches to Stop Hypertension, which are recognized to show lower incidence of certain chronic diseases and long-life expectancy (Eilat-Adar, Sinai, Yosefy, & Henkin, 2013; Vasto et al., 2014) .
In particular, dietary bres confer the property of functional if fi added to food for their capacity to positively in uence coronary artery fl health, cholesterol reduction, glucose metabolism, insulin response, blood lipids, and cancer (Baldassano, Accardi & Vasto, 2017; Carruba et al., 2016) .
In a recent pilot study, it was considered the e ects on health of ff 30 days intake of pasta enriched with 6% of -glucan, demonstrating a β signi cant decrease of low density lipoprotein (LDL)-cholesterol, infi terleukin-6 and advanced glycation end-products, and con rming the fi capacity of -glucans intake to lower oxidative stress and in ammatory β fl status ( ). Barera et al., 2016 β-glucan is a high-molecular non-starch polysaccharide consisting of -(1-4)-and -(1-3)-linked -D-glucopyranosyl-subunits, in varying β β β proportions. They are random coils, or linear molecules with kinks caused by the -1-3 linkages ( ). They are β AbuMweis, Jew, & Ames, 2010 present in many cell walls of yeasts, fungi, bacteria, algae and cereals. Among these, barley and oat have a relatively higher -glucan content, β between 2% and 10% (weight/weight) ( ). Decker, Rose & Stewart, 2014 In order to understand the role of -glucan in intestinal hormone β release and achieving satiety, we analysed blood levels of some gut hormones, after -glucan intake. β Gut hormones modulate glucose tolerance and food intake through a variety of mechanisms, including satiety. So, these hormones might therefore be excellent therapeutic candidates for the treatment of metabolic syndrome ( ). Ames et al., 2015; Fändriks, 2017 The most widely studied appetite modulating intestinal hormones are glucagon-like peptide 1 and 2 (GLP-1, GLP-2), cholecystokinin (CCK), peptide tyrosine-tyrosine (PYY) and peptide ghrelin (Horner & Lee, 2015; Lean & Malkova, 2016) .
So far, ghrelin is the only known circulating orexigenic satiety-related hormone and its exogenous administration has been shown to stimulate appetite and food intake, both in rats and in humans (Mani & Zigman, 2017) .
In contrast to ghrelin, GLP-1, GLP-2 and PYY are secreted into the circulation following meal ingestion and decrease with fasting ( ). The adminisBaldassano & Amato, 2014; De Silva & Bloom, 2012 tration of GLP-1 reduces hunger and energy intake in both animals and humans (
). Its post-prandial production is blunted Nauck & Meier, 2018 in severely obese people but controversy exists if its concentration tends to normalize following body weight reduction (Gibbons et al., 2013; Nauck & Meier, 2018) . Moreover, its pharmacological activation has bene cial e ects on obesity-induced alterations of lipoprotein metafi ff bolism.
The role of GLP-2-related pathways on lipid levels and metabolism are less clear, but some e ects are opposite to GLP-1 ( ff Baldassano, Amato, & Mulè, 2016; Baldassano, Amato, Rappa, Cappello, & Mulè, 2016; Lutz & Osto, 2016) .
The intestinal hormone PYY seems to reduce food intake in normalweight and obese rodents and repeated infusion attenuates weight gain ( ). De Silva & Bloom, 2012 CCK is anorexigenic hormone that is co-expressed with PYY, leading to food intake and body weight decreasing, as well as, fullness perception. It is responsible of meal termination and is released by protein and ingestion of fatty food. In rodent, CCK administration triggers dosedependent decrease in food intake and meal size ( ). Mari , et al., 2014 ć The present study investigated the use of pasta forti cated with 6% fi β-glucan on healthy overweight individuals. We developed a single arm longitudinal intervention study ( ) that was carried out with Thiese, 2014 the objective of better understanding the relationship among the consumption of this pasta and lipid pro le, intestinal hormones release, fi and satiety. In particular, we investigated the modi cation of the serum fi concentrations of orexigenic peptide ghrelin and anorexigenic active form of GLP-1, GLP-2, CCK, and PYY.
Material and methods

Study design
The nutritional intervention was a single arm longitudinal intervention study, consisting in the weekly consumption of 400 g of pasta supplemented with 6% of -glucans in 10 overweight young Sicilian β people, for 30 days. We performed hematochemical and anthropometric tests at baseline (day 0), and after 30 days (day 30) of the nutritional intervention.
They received suggestions how to maintain unaltered -glucans β content during cooking.
All the tests were performed between 8:00 and 9:00 a.m., in postabsorptive night fasting from at least 10 h, without any strenuous physical activity in the last three days. Samples in fasting were used for hematochemical test. To obtain many di erent blood samples, an inff dwelling venous cannula was placed in the forearm to test variation in the intestinal hormones among fasting and 15, 30, 60, 90, 180 min after the ingestion of the test meal. The samples were immediately centrifuged to collect serum, and stored at 80°C. Intestinal hormones − measured were GLP-1, ghrelin, PYY, CCK, and GLP-2.
The participants evaluated their sensation of satiety before eating the test meal and after 180 min, respectively, using the visual analogue scale (VAS) as recommended by Flint, Raben, Blundell, and Astrup (2000) . The evaluated sensations were hunger, satiety, desire to eat and prospective food consumption.
Moreover, anthropometric measurements (height in cm, weight in kg) were collected and body mass index (BMI, kg/m 2 ) was calculated. The study protocol was conducted in accordance with the Declaration of Helsinki and its amendments, and was approved by the local review board (protocol n. 032017). Suitable subjects were identi ed from volunteer group, according to the inclusion and exclusion fi criteria (see below) and were contacted by one physician (SB) personally or by telephone. All eligible candidates had to provide signed informed consent before enrolment in the study.
Recruitment criteria
This study was performed in healthy overweight individuals. , normal glucose tolerance (fasting plasma glucose < 100 mg/dL, glycated haemoglobin < 5.7%), slight dyslipidaemia if any (total cholesterol < 240 mg/dL, LDL < 160 mg/dL, triglyceride levels < 200 mg/dL). Exclusion criteria were: any diagnosis of systemic disorder (including heart disease, hypertension, rheumatologic disease, liver, kidney and intestinal disorders), any drug treatment, eating behaviour disease based on VAS questionnaire (Flint et al., 2000) , and any hypocaloric dietary treatment in the last six months. Enrolled people underwent a complete medical evaluation by a trained physician (SB). It was recommended no other changes in dietary and lifestyle habits except to switch from wheat our based pasta tofl β glucans based pasta. Also, it was suggested to avoid any other source of β-glucans during the study period.
All the subjects ended the pilot study (100% of trial completion).
Hematochemical, intestinal hormones, and anthropometric tests
The recruited participants underwent venepuncture, after a fasting period of 10 12 h, at day 0 and day 30. Blood samples were collected in -speci c tubes containing EDTA for plasma analyses, and in serum tubes fi with no additives. Serum and plasma samples were used for hematochemical and intestinal hormones tests, respectively. For hematochemical tests, the following parameters were analysed: glucose, total cholesterol, high density lipoprotein cholesterol, LDL-cholesterol, triglycerides, blood counts, aspartate aminotransferase (AST), and alanine transaminase (ALT). For intestinal hormones measurement, plasma was obtained from peripheral blood sample by centrifugation at 5°C for 10 min at 3000 rpm and collected in prechilled EDTA-containing tubes with apoprotein (0.6 TIU/ml blood) and dipeptidyl peptidase IV inhibitor (10 µl/ml blood). All samples were immediately stored at −80°C until analysed.
Body weight, height and blood pressure of all participants were measured and blood samples were collected at day 0 (baseline) and at day 30 (end of the intervention). Results were obtained from all the study participants. Samples were analysed using the following enzyme immunoassay kit: EGLP-35K for active GLP-1, EZGRT-89K for total ghrelin, EZHPPYYT66K for total PYY, EZGLP-237K for GLP-2, all from Millipore (EMD Millipore, MERCK KGaA, Darmstadt, Germany) CCK for CCK from Phoenix (PHOENIX PHARMACEUTICALS, INC. Burlingame, CA 94010). These kits are enzyme immunoassays developed for the detection and quantization of the di erent hormones in plasma, serum ff or other tissue culture methods. Each kit provides su cient reagents to ffi perform up to 96 assays including standard curve and unknown sample. The detection method is uorescent and/or colorimetric. fl
Pasta production
The pasta used to perform the experiments was produced by mixing durum wheat ( Desf.) semolina with barley ( Triticum durum Hordeum vulgare L.) our containing 11% (weight/weight) of -glucans. Barley fl β flour Beta Barley Flour 11 was provided by the Agroalimentare Sud " " S.p.A. (Mel , Italy). For durum wheat, grains of cv. Vertola (released in fi 2003 by the University of Palermo, Italy) were milled to semolina by means of a MLU 202 mill (Buhler, Uzwil, Switzerland), after conditioning at 17.5% moisture. Semolina quality characteristics of cv. Vertola are reported in . About 10 kg of -glucan-enriched pasta Table 1 β were produced by mixing semolina to barley our in the ratio of 70:30 fl (weight/weight) and adding an amount of water equal to 36% by weight of the mixture. This value was chosen as the best proportion of water to be added to the semolina-barley our mixture to obtainfl β glucan-enriched pastas with characteristics compliant with the standards required for consumption after a number of tests where increasing amounts of water (from 30 to 60%) were used. The dough, extruded through a Te on die, was shaped into ditalini rigati (diafl " " meter 9.0 mm). Then the extruded pasta was dried in a static dryer (LAB, Namad Impianti, Rome, Italy). Final starch content was 70% (w/ w). Microbial risk assessment in food processing was done. The organoleptic features of the -glucan enriched pasta (brown color, sweet β taste, di erent smell) led us to exclude the possibility to test a control ff pasta because we hypothesized no compliance (people would be conscious of the absence of extract so of the absence of possible bene cial fi e ect) in our study design. Dried pasta was stored in sealed bags at ff room temperature until use. The batch of ditalini pasta used in this study had a -glucans concentration of 6% calculated using the protocol β by . Montalbano et al (2016) 
Statistical analysis
Results are shown as mean ± S.E.M. for intestinal hormones, S.D. used for hematochemical tests. The comparison of hematochemical tests before and after the 30 days of pasta intake was performed by Wilcoxon test. The comparison between the levels of gut hormones after test meal at baseline and after 30 days was performed by ANOVA followed by Bonferroni s post-test test using Prism Version 6.0 Software ' (Graph Pad Software, Inc., San Diego, CA, USA).
The area under the curve (AUC) values were calculated using the trapezoidal rule. In the eld of pharmacokinetics, the AUC is the area fi under the curve in a plot of concentration of drug in blood plasma against time. In this case, it determines whether the same standardized two formulations of test meal, before and after 30 days treatment within pasta added with -glucans, release the same dose of hormones. β A p value < 0.05 was considered to be statistically signi cant. fi
Results
Hematochemical tests
Anthropometric and biochemical measurements are presented in Barera et al., 2016 AST and ALT concentrations were in the range of normality and did not show any signi cant modi cation along the study (data not shown).
fi fi Body weight and BMI did not vary along the 30 days since the participant were asked to do not modify their nutritional habits.
Gut hormone responses
GLP-1 (
). Fasting levels of active GLP-1 were 2 ± 0.2 pmol/l Fig. 1 at day 0 and increased to 3.6 ± 0.3 pmol/l at day 30. The consumption of test meal induced an increase in plasma GLP-1 concentrations, starting from 15 min up to 90 min, peaking at 30 min. The consumption of the -glucans enriched pasta for 30 days signi cantly increased the β fi levels of GLP-1 at 0, 30 and 60 min after intake. As shown by AUC, on the whole, after 30 days treatment we observed an increased release of GLP-1.
Ghrelin ( ). Plasma ghrelin concentrations were higher in Fig. 2 fasting state (220 ± 35 pg/ml) and they were reduced following the test-meals. The consumption of the -glucans enriched pasta for 30 days β causes levels of ghrelin higher during fasting measured at day 30 (400 ± 45 pg/ml) with respect to the values measured at day 0. However, the slope of ghrelin during time was reduced more after the treatment than at day 0. This suggests that the response to the test meal is more e ective to reduce and achieve satiety after the treatment. In ff fact, the level of ghrelin was maintained over the time after the treatment. Instead, at the beginning of the study, ghrelin shows a tendency to increase immediately after 90 min. So, the return to the fasting level is achieved earlier than in the treated group.
PYY ( ). Fasting levels of total PYY were 153 ± 9.3 pg/ml at Fig. 3 day 0 and increased to 306 ± 28 pg/ml at day 30. The consumption of test meal induced an increase in plasma PYY concentrations starting from 15 min up to 90 min, peaking at 90 min. The consumption of the -β glucans enriched pasta for 30 days signi cantly increased the levels of fi PYY at 0, 15, 30, 60 and 90 min after intake. As shown by AUC, on the whole, after 30 days treatment we observed an increased release of PYY. 
GLP-2 and CCK (
). At day 0, plasma CCK concentrations were Fig. 4 lower in fasting state (0.069 ± 0.01 ng/ml) than after 180 min and they were increased following the test-meals. For GLP-2 no di erences ff were observed in plasma concentrations during fasting (3.0 ± 0.4 ng/ ml) or after 180 min.
At day 30, the consumption of the -glucans enriched pasta did not β a ect plasma concentrations of GLP-2 and CCK (CCK 0.063 ± 0.01 ng/ ff ml; GLP-2 2.2 ± 0.16 ng/ml).
Discussion
The results of the present research provide knowledge about the e ect of pasta, forti ed with -glucan bre, consumption on di erent ff fi β fi ff physiological factors linked with glycaemic level, satiety and intestinal hormones response. To the best of our knowledge, the present study is one of the many investigating the e ect of foods enriched with -gluff β cans on glycaemia levels and lipid pro le ( Characteristic already known of -glucans is the e ect on lowering β ff cholesterol and glycaemia levels. This e ect depends on the ability to ff form a viscous layer on the surface of the small intestine slowing gastric emptying, digestion, and absorption of molecules as glucose and dietary cholesterol on bile acids. Furthermore, the reduction of the blood glucose levels is associated with short chain fatty acids formed by the microbial fermentation of bre carbohydrates. 2006; Chillo et al., 2011; Granfeldt, Liljeberg, Drews, Newman, & Björck, 1994; Pentikäinen et al., 2014; Thondre, Wang, Rosenthal, & Henry, 2012) , so we can propose that the regular intake of pasta added with -glucans should be a promising tool to prevent obesity by β food intake reduction.
Obesity is responsible of activating in ammatory process in metafl bolically active sites, producing several in ammatory mediators that fl might determine a chronic active in ammatory condition that is fl associated with the development of the obesity-related in ammatory fl diseases ( ). Balistreri, Caruso & Candore, 2010 It is to note that our study presents some limitations. One is strictly related to the intrinsic complexity of human as study model and to the inter/intra-individual variability. The second is that we can consider this study only a pilot one due to the small sample size (10 people), which is not enough to completely cover the genetic and individual variability. The third is strictly related to the study design: it is a single arm, widely used in medical studies for the complexity of human system ( ). Thus, we did not administrate pasta without -glucans Thiese, 2014 β due to its di erent organoleptic features (brown color, sweet taste, ff di erent smell) that could alter the compliance to the study. So, further ff analyses might be necessary to con rm our pilot study. fi Overall, the present study indicates that consumption of pasta with β-glucans could alter glycaemia, lipid and intestinal hormones levels. This opens new opportunities to functional food optimization in order to obtain healthy bene ts. The results indicate that pasta enriched with fi β-glucans might be part of dietary suggestions in obesity management prevention. Furthermore, other study population, using di erentff β glucans concentration and wider population, as well as population affected by metabolic syndrome, are needed.
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